NASDAQ:AMRN - Amarin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.33 0.00 (0.00 %)
(As of 11/21/2018 07:22 AM ET)
Previous Close$17.33
Today's Range$16.28 - $17.48
52-Week Range$2.35 - $23.33
Volume7.23 million shs
Average Volume14.87 million shs
Market Capitalization$5.07 billion
P/E Ratio-69.32
Dividend YieldN/A
Beta0.7
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
Previous Symbol
CUSIPN/A
Phone353-1669-9020

Debt

Debt-to-Equity RatioN/A
Current Ratio1.33
Quick Ratio1.05

Price-To-Earnings

Trailing P/E Ratio-69.32
Forward P/E Ratio-48.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.10 million
Price / Sales27.97
Cash FlowN/A
Price / CashN/A
Book Value($0.26) per share
Price / Book-66.65

Profitability

EPS (Most Recent Fiscal Year)($0.25)
Net Income$-67,860,000.00
Net Margins-51.15%
Return on EquityN/A
Return on Assets-53.17%

Miscellaneous

Employees241
Outstanding Shares292,320,000
Market Cap$5.07 billion
OptionableOptionable

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biopharmaceutical company had revenue of $55 million for the quarter, compared to analysts' expectations of $60.63 million. The company's revenue was up 16.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

5 Wall Street analysts have issued twelve-month price objectives for Amarin's stock. Their predictions range from $15.00 to $51.00. On average, they anticipate Amarin's share price to reach $31.80 in the next twelve months. This suggests a possible upside of 83.5% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. HC Wainwright analysts commented, "We believe that beyond the topline of 25% reduction of MACE score, the robustness of the data is highlighted by the consistency across pre-specified analyses. A key secondary composite, namely 3-point MACE score (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), which assesses the major CV events (and reflects the most important clinical relevance), showed an even higher reduction of risks at 26% compared to placebo. The clinical benefits as measured by the primary endpoint of MACE score and the key secondary 3-point MACE score are observed across subgroups (statistically significant in the vast majority of the subgroups), which speaks to the validity and robustness of the data." (11/12/2018)
  • 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, positive REDUCE-IT data, and ahead of what we expect to be more good data for REDUCE-IT at AHA on 11/10, we are reiterating our OW rating and 12-month PT of $35 for AMRN shares. We believe that the addressable market opportunity for Vascepa is still underappreciated, and that upwards earnings revisions of the peak sales for the drug should drive AMRN’s stock higher. The 3Q18 earnings call starts 7:30AM ET." (11/1/2018)
  • 3. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (8/8/2018)

Has Amarin been receiving favorable news coverage?

Press coverage about AMRN stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amarin earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.

Are investors shorting Amarin?

Amarin saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 17,500,650 shares, an increase of 34.1% from the October 15th total of 13,052,628 shares. Based on an average daily volume of 10,687,612 shares, the short-interest ratio is currently 1.6 days. Approximately 6.0% of the shares of the company are sold short. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Pres, CEO & Director (Age 57)
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 47)
  • Dr. Steven B. Ketchum, Pres of R&D, Sr. VP and Chief Scientific Officer (Age 53)
  • Mr. Joseph T. Kennedy, Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)
  • Ms. Elisabeth Schwartz, Sr. Director of Investor Relations

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (11.65%), Oracle Investment Management Inc. (2.00%), Sofinnova Ventures Inc (1.78%), BlackRock Inc. (1.16%), Morgan Stanley (1.10%) and Point72 Asset Management L.P. (0.89%). Company insiders that own Amarin stock include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Stonepine Capital Management LLC, Sofinnova Ventures Inc, Morgan Stanley, Opaleye Management Inc., Wells Fargo & Company MN, Hsbc Holdings PLC and LPL Financial LLC. Company insiders that have sold Amarin company stock in the last year include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Point72 Asset Management L.P., EULAV Asset Management, Rubric Capital Management LP, C WorldWide Group Holding A S, Perceptive Advisors LLC, Oracle Investment Management Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $17.33.

How big of a company is Amarin?

Amarin has a market capitalization of $5.07 billion and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  568 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  912
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel